Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (NASDAQ: RGEN) is a global life sciences company specializing in the development, production, and commercialization of innovative bioprocessing technologies and systems that enhance the efficiency of biological drug manufacturing. Headquartered in Waltham, Massachusetts, the company operates additional manufacturing facilities in Sweden, Estonia, France, Germany, Ireland, the Netherlands, and the United States.
Repligen is renowned for its high-quality bioprocessing products, which are essential in the production of biological drugs. The company's product portfolio includes Protein A, a critical reagent used in the manufacturing of monoclonal antibody-based therapeutics, and several growth factor products that boost cell culture productivity in biomanufacturing. Additionally, Repligen offers OPUS™ (Open Platform User Specified) single-use chromatography columns, which are pivotal in the biologics purification process.
The company serves a diverse customer base that includes major life sciences and biopharmaceutical companies, as well as contract development and manufacturing organizations (CDMOs) worldwide. Repligen markets its products globally through a direct sales organization in the U.S., Europe, and Asia, complemented by strategic partnerships in select regions. North America remains the primary market, contributing the majority of the company's revenue.
Recent achievements include the acquisition of Metenova AB, a leading innovator in magnetic mixing technologies, to expand its Fluid Management portfolio. Despite challenges in the bioprocessing market, Repligen continues to exhibit resilience with steady revenue growth, particularly in its Analytics and Chromatography franchises.
Financially, Repligen reported second quarter revenues of $159.2 million in 2023 and has adjusted its full-year revenue guidance to a range of $635-$665 million. The company remains optimistic about overcoming current market headwinds, with a growing pipeline of opportunities expected to bolster orders in the fourth quarter.
Overall, Repligen's commitment to bioprocessing technology leadership and continuous innovation positions it as a significant player in the life sciences industry, driving advancements that support the development of life-saving biological drugs.
Repligen Corporation (NASDAQ:RGEN) will report its Q4 and full year 2021 financial results on February 17, 2022. A press release will be issued prior to market opening, and a conference call is scheduled for 8:30 a.m. EST to discuss the results and business updates for the periods ending December 31, 2021. The call can be accessed via toll-free numbers or through a webcast.
Repligen Corporation (NASDAQ:RGEN) will participate virtually in the 40th Annual J.P. Morgan Healthcare Conference from January 10-13, 2022. CEO Tony J. Hunt is scheduled to present on January 12 at 9:45 a.m. EST. Investors can access a live webcast of the presentation on Repligen’s Investor Relations website, with a replay available for a limited time post-event. Repligen is a leader in developing innovative bioprocessing technologies that enhance the manufacturing of biological drugs, serving biopharmaceutical developers and CDMOs globally.
Repligen Corporation (NASDAQ:RGEN) announced its participation in two investor conferences. The first is Stifel’s 2021 Virtual Healthcare Conference from November 15-17, where CEO Tony J. Hunt will hold a fireside chat on November 17 at 8:00 a.m. EST. The second is the Stephens Annual Investment Conference from December 1-3, featuring CFO Jon K. Snodgres on December 3 at 11:00 a.m. EST. Live webcasts will be accessible through the Investor Relations section of the company’s website, with replays available thereafter.
Repligen Corporation (NASDAQ:RGEN) reported record revenue of $178.2 million for Q3 2021, reflecting an 89% year-over-year growth and 77% organic growth. The company raised its full-year revenue guidance to $655-$665 million. Key highlights include a 49% organic growth from its base business and significant contributions from COVID-related sales, which rose 247%. The gross margin improved to 58.3%, and the fully diluted EPS increased to $0.58. The positive trajectory is attributed to strategic acquisitions and growth in gene therapy revenue.
Repligen Corporation (NASDAQ:RGEN) will release its third quarter 2021 financial results on October 28, 2021, prior to market open. A conference call will follow at 8:30 a.m. EDT to discuss business updates and results for the three- and nine-month periods ending September 30, 2021. Interested parties can access the call by dialing specific numbers based on their location. Repligen, a life sciences company, focuses on innovative bioprocessing technologies for biopharmaceutical manufacturers globally. More details can be found on their website.
Repligen Corporation (NASDAQ:RGEN) has entered into a definitive agreement to acquire Avitide Inc. for approximately $150 million. The deal includes $75 million in cash and $75 million in Repligen common stock, alongside performance-based earnouts over three years. This acquisition aims to enhance Repligen’s Proteins business, particularly in affinity ligand solutions for gene therapy, with Avitide expected to contribute about $10 million in revenue in 2022 and positively impact adjusted earnings per share in 2023.
Repligen Corporation (NASDAQ:RGEN) and Navigo Proteins GmbH announced the successful development of a novel protein A ligand called NGL-Impact A Hi pH. This innovative ligand addresses critical challenges in purifying pH sensitive antibodies and Fc-fusion proteins, notably reducing antibody aggregation during purification. Customer evaluations showcased a two-fold decrease in aggregate formation while maintaining high dynamic binding capacity. The ligand is set for commercialization via a new resin later this year, potentially offering significant cost and time savings for developers in the biopharmaceutical industry.
Repligen Corporation (NASDAQ:RGEN) reported Q2 2021 revenue of $163.0 million, achieving an 86% year-over-year growth and 69% organic growth. The company raised its revenue guidance for 2021 to $625-$645 million from previous estimates of $565-$590 million. The acquisition of Polymem S.A. further enhances Repligen's capabilities. Key financial metrics include a GAAP EPS of $0.64 and adjusted EPS of $0.79 for the quarter. The company anticipates a gross margin of 59%-60% for the year, reflecting ongoing strong performance.
Repligen Corporation (NASDAQ:RGEN) will report its Q2 2021 financial results on July 27, 2021. A press release will be issued before the market opens, followed by a conference call at 8:30 a.m. EDT to discuss financial results for the three- and six-month periods ending June 30, 2021. Domestic callers can dial (844) 274-3999, while international callers can use (412) 317-5607. The call will also be available via a webcast on the company’s Investor Relations webpage, with archived access provided as well.
FAQ
What is the current stock price of Repligen (RGEN)?
What is the market cap of Repligen (RGEN)?
What does Repligen Corporation specialize in?
Where is Repligen's headquarters located?
What are some key products offered by Repligen?
Who are Repligen's primary customers?
How does Repligen market its products?
What recent acquisition has Repligen made?
What was Repligen's revenue for the second quarter of 2023?
What is Repligen's revenue guidance for the year 2023?
Which regions contribute the most to Repligen's revenue?
What is Repligen's focus area?
